Pancreatic Neoplasms Clinical Trial
Official title:
Distal Pancreatectomy With Multivisceral Resection: A Multicentric Study
The objective of the study is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy.
Multicenter study that includes patients operated on for distal pancreatectomy between
January 2009 to December 2019 for primary pancreatic tumors. Both open or laparoscopic
approaches are considered in the study. The objective is to evaluate the characteristics of
the patients and the results of morbidity and mortality after distal pancreatectomy isolated
or accompanied by multivisceral resection including cholecystectomy. For this, demographic
data, variables related to the tumor, surgical intervention and postoperative evolution were
collected.
Definitions:
Diagnosis was based mainly on computed tomography (CT scan), Magnetic Resonance (MRI) and
endoscopic ultrasonography (USE) plus biopsy. Surgical technique includes open and
laparoscopic approach with or without spleen preservation. Complications were assessed at 90
days using the Clavien - Dindo classification, and those defined as Clavien - Dindo grade
IIIA or higher were considered major. For the recording of complications, the medical and
nursing notes of the electronic or histories of each patient were consulted. For the specific
complications of pancreatic surgery, the definitions of the International Study Group on
Pancreatic Surgery (ISGPS) of delayed gastric emptying (21), post-pancreatic hemorrhage (22)
and pancreatic fistula were used. The resection margins of the surgical specimen were
categorized according to the definitions of the Royal College of Pathologists: R0 (margin to
the tumor ≥ 1mm), R1 (margin to the tumor <1mm) and R2 (macroscopically positive margin)
(24). Tumors were staged according to the TNM classification 8 º Ed. (TNM). Follow up scheme
was: 6-month outpatient clinic visit during first five years including tumoral markers and
CT/MRI. After five years only once a year visit policy was applied.
Variables The following variables were studied: Epidemiological: age, sex, past medical
history, medication, Charlson Index and American Society of Anesthesiology (ASA)
classification; Clinical: symptoms due to mucinous neoplasm (MCN); Serological tests:
leukocytes, amylase; hemoglobin (gr/dl), bilirubin, creatinin, prothrombin time,
carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9; Radiological/diagnostic:
diagnostic tests performed (CT/MRI/EUS), number, size and location of MCN, vascular
infiltration (arterial and venous) and preoperative biopsy; Surgical: type of approach
(open/laparoscopy/conversion), spleen preservation, associated procedures (organs resected),
type of closure of pancreatic remnant, intraoperative bleeding (ml); postoperative course:
morbidity and mortality (according to the Clavien-Dindo (CD) classification) (13), pancreatic
fistula, postoperative hemorrhage and delayed gastric empting, if present, was classified
according to the International Group Study Pancreatic Surgery (IGSPS) classification (14,15),
hospital stay and readmissions. The histological data retrieved were TNM: tumor size and
lymph nodes harvested and R status. Postoperative follow-up (months) including endocrine and
exocrine insufficiency rate.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
| Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
| Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
| Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
| Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
| Completed |
NCT00136669 -
Acupuncture For Pancreatic Cancer Pain
|
Phase 3 |